Edgewise Therapeutics (EWTX) Change in Acquisitions & Divestments (2021 - 2026)
Edgewise Therapeutics has reported Change in Acquisitions & Divestments over the past 6 years, most recently at $4.0 million for Q1 2026.
- Quarterly results put Change in Acquisitions & Divestments at $4.0 million for Q1 2026, down 97.38% from a year ago — trailing twelve months through Mar 2026 was $280.2 million (up 158.9% YoY), and the annual figure for FY2025 was $427.3 million, up 2605.51%.
- Change in Acquisitions & Divestments reached $4.0 million in Q1 2026 per EWTX's latest filing, down from $375.9 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $375.9 million in Q4 2025 and bottomed at -$258.3 million in Q4 2023.
- Median Change in Acquisitions & Divestments over the past 5 years was $59.8 million (2022), compared with a mean of $39.1 million.
- The largest annual shift saw Change in Acquisitions & Divestments tumbled 469.69% in 2023 before it surged 12126.94% in 2025.
- Over 5 years, Change in Acquisitions & Divestments stood at $69.9 million in 2022, then crashed by 469.69% to -$258.3 million in 2023, then skyrocketed by 101.19% to $3.1 million in 2024, then soared by 12126.94% to $375.9 million in 2025, then tumbled by 98.94% to $4.0 million in 2026.
- Business Quant data shows Change in Acquisitions & Divestments for EWTX at $4.0 million in Q1 2026, $375.9 million in Q4 2025, and -$177.7 million in Q3 2025.